Document Classification

Section Type: RESULTS

Text: Rosiglitazone administration induced a significant decrease in glucose concentration (4. 7 + / - 0. 1 vs. 4. 4 + / - 0. 1 mmol/l, p < 0. 005) and insulin-circulating level (13. 6 + / - 1. 5 vs. 8. 0 + / - 0., 7 microU/ml, p < 0. 005), an increase in insulin sensitivity as measured by homeostatic model assessment (HOMA) of insulin sensitivity (68. 9 + / - 8. 8 vs. 109. 9 + / - 10. 3, p < 0. 005) with a concomitant decrease in beta-cell function as measured by HOMA of beta-cell function (163. 2 + / - 16. 1 vs. 127. 4 + / - 8. 4, p < 0. 005).